Fibroblast growth factor 23 and its role in bone diseases
2023; Taylor & Francis; Volume: 42; Issue: 1 Linguagem: Inglês
10.1080/08977194.2023.2274579
ISSN1029-2292
AutoresAndrija Jurina, Dino Kasumović, Valentina Delimar, Tajana Filipec Kanižaj, Mladen Japjec, Tomislav Dujmović, Marijana Vučić Lovrenčić, Mario Starešinić,
Tópico(s)Bone health and osteoporosis research
ResumoFibroblast growth factor 23 (FGF23) has been casually linked to numerous hypophosphatemic bone diseases, however connection with bone loss or fragility fractures is still a matter of debate. The purpose of this review is to explore and summarise the known actions of FGF23 in various pathological bone conditions. Besides implication in bone mineralisation, elevated FGF23 showed a pathological effecton bone remodelling, primarily by inhibiting osteoblast function. Unlike the weak association with bone mineral density, high values of FGF23 have been connected with fragility fracture prevalence. This review shows that its effects on bone are concomitantly present on multiple levels, affecting both qualitative and quantitative part of bone strength, eventually leading to impaired bone strength and increased tendency of fractures. Recognising FGF23 as a risk factor for the development of bone diseases and correcting its levels could lead to the reduction of morbidity and mortality in specific groups of patients.
Referência(s)